

01 cont
x% sequence identity to SEQ ID NO:5; and at least one of N₁ or N₅ is present, but N₂, N₃, N₄ and polyA are optional.

02
16. (Amended) Isolated polynucleotide of claim 16, comprising one of SEQ ID NOS:7-39, SEQ ID NOS:44-45, SEQ ID NOS:59-91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NOS:99-102, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NOS:110-145, SEQ ID NOS:150-157, or SEQ ID NOS:161-225.

03
20. (Amended) Isolated polynucleotide of claim 21, wherein B comprises a fragment of 7 or more nucleotides from one or more of SEQ ID NOS:7-39, 44-45, 59-91, 93, 95, 97, 99-102, 105, 107, 110-145, 150-157, and 161-225.

25. (Amended) An isolated polypeptide for use in the diagnosis of prostate cancer, the polypeptide comprising: (a) an amino acid sequence selected from the group consisting of SEQ ID NOS:109, 146, 147, 148 and 149; (b) a fragment of at least 7 amino acids of (a); or (c) a polypeptide sequence having at least 50% identity to (a).

04
26. (Amended) An isolated polypeptide having formula NH₂-A-B-C-COOH, wherein: A is a polypeptide sequence consisting of *a* amino acids; C is a polypeptide sequence consisting of *c* amino acids; B is a polypeptide sequence consisting of a fragment of at least 5 amino acids of an amino acid sequence selected from the group consisting of SEQ ID NOS:146, 147, 148, 149, and 109; and said polypeptide is not a fragment of polypeptide sequence SEQ ID NO:146, 147, 148, 149, or 109; and wherein $a+c>1$.
